Maternal hybrid immunity and risk of infant COVID-19 hospitalizations: national case-control study in Israel.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
02 Apr 2024
02 Apr 2024
Historique:
received:
21
07
2023
accepted:
05
03
2024
medline:
3
4
2024
pubmed:
3
4
2024
entrez:
2
4
2024
Statut:
epublish
Résumé
Hybrid immunity, acquired through vaccination followed or preceded by a COVID-19 infection, elicits robust antibody augmentation. We hypothesize that maternal hybrid immunity will provide greater infant protection than other forms of COVID-19 immunity in the first 6 months of life. We conducted a case-control study in Israel, enrolling 661 infants up to 6 months of age, hospitalized with COVID-19 (cases) and 59,460 age-matched non-hospitalized infants (controls) between August 24, 2021, and March 15, 2022. Infants were grouped by maternal immunity status at delivery: Naïve (never vaccinated or tested positive, reference group), Hybrid-immunity (vaccinated and tested positive), Natural-immunity (tested positive before or during the study period), Full-vaccination (two-shot regimen plus 1 booster), and Partial-vaccination (less than full three shot regimen). Applying Cox proportional hazards models to estimate the hazard ratios, which was then converted to percent vaccine effectiveness, and using the Naïve group as the reference, maternal hybrid-immunity provided the highest protection (84% [95% CI 75-90]), followed by full-vaccination (66% [95% CI 56-74]), natural-immunity (56% [95% CI 39-68]), and partial-vaccination (29% [95% CI 15-41]). Maternal hybrid-immunity was associated with a reduced risk of infant hospitalization for Covid-19, as compared to natural-immunity, regardless of exposure timing or sequence. These findings emphasize the benefits of vaccinating previously infected individuals during pregnancy to reduce COVID-19 hospitalizations in early infancy.
Identifiants
pubmed: 38565530
doi: 10.1038/s41467-024-46694-x
pii: 10.1038/s41467-024-46694-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2846Informations de copyright
© 2024. The Author(s).
Références
Cui, X. et al. A systematic review and meta-analysis of children with coronavirus disease 2019 (COVID-19). J. Med. Virol. 93, 1057–1069 (2021).
doi: 10.1002/jmv.26398
pubmed: 32761898
Hobbs, C. V. et al. Frequency, characteristics and complications of COVID-19 in hospitalized infants. Pediatr. Infect. Dis. J. 41, e81–e86 (2022).
doi: 10.1097/INF.0000000000003435
pubmed: 34955519
Marks, K. J. et al. Hospitalization of infants and children aged 0–4 years with laboratory-confirmed COVID-19—COVID-NET, 14 states, March 2020–February 2022. Morbid. Mortal. Wkly Rep. 71, 429 (2022).
doi: 10.15585/mmwr.mm7111e2
Jorgensen, S. C. J. et al. Maternal mRNA covid-19 vaccination during pregnancy and delta or omicron infection or hospital admission in infants: test negative design study. BMJ 380, e074035 (2023).
doi: 10.1136/bmj-2022-074035
pubmed: 36754426
Villar, J. et al. Pregnancy outcomes and vaccine effectiveness during the period of omicron as the variant of concern, INTERCOVID-2022: a multinational, observational study. Lancet 401, 447–457 (2023).
doi: 10.1016/S0140-6736(22)02467-9
pubmed: 36669520
pmcid: 9910845
Switzer, C., D’Heilly, C. & Macina, D. Immunological and clinical benefits of maternal immunization against pertussis: a systematic review. Infect. Dis. Ther. 8, 499–541 (2019).
doi: 10.1007/s40121-019-00264-7
pubmed: 31535327
pmcid: 6856250
Schlaudecker, E. P. et al. IgA and neutralizing antibodies to influenza a virus in human milk: a randomized trial of antenatal influenza immunization. PLoS ONE 8, e70867 (2013).
doi: 10.1371/journal.pone.0070867
pubmed: 23967126
pmcid: 3743877
Blencowe, H., Lawn, J., Vandelaer, J., Roper, M. & Cousens, S. Tetanus toxoid immunization to reduce mortality from neonatal tetanus. Int. J. Epidemiol. 39, i102–i109 (2010).
doi: 10.1093/ije/dyq027
pubmed: 20348112
pmcid: 2845866
Kampmann, B. et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N. Engl. J. Med. 388, 1451–1464 (2023).
doi: 10.1056/NEJMoa2216480
pubmed: 37018474
Guedalia, J. et al. Effectiveness of a third BNT162b2 mRNA COVID-19 vaccination during pregnancy: a national observational study in Israel. Nat. Commun. 13, 6961 (2022).
doi: 10.1038/s41467-022-34605-x
pubmed: 36379951
pmcid: 9664047
Lipschuetz, M. et al. Maternal third dose of BNT162b2 mRNA vaccine and risk of infant COVID-19 hospitalization. Nat. Med. 29, 1155–1163 (2023).
Halasa, N. B. et al. Maternal vaccination and risk of hospitalization for Covid-19 among infants. N. Engl. J. Med. 387, 109–119 (2022).
doi: 10.1056/NEJMoa2204399
pubmed: 35731908
Nevo, L. et al. Boosting maternal and neonatal humoral immunity following SARS-CoV-2 infection using a single messenger RNA vaccine dose. Am. J. Obstet. Gynecol. 227, 486.e1–486.e10 (2022).
doi: 10.1016/j.ajog.2022.04.010
pubmed: 35430228
Bobrovitz, N. et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. Lancet Infect. Dis. 23, 556–567 (2023).
doi: 10.1016/S1473-3099(22)00801-5
pubmed: 36681084
pmcid: 10014083
Powell, A. A. et al. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study. Lancet Infect. Dis. 23, 435–444 (2023).
doi: 10.1016/S1473-3099(22)00729-0
pubmed: 36436536
Szczygioł, P. et al. Antibodies in the breastmilk of COVID-19 recovered women. BMC Pregnancy Childbirth 22, 635 (2022).
doi: 10.1186/s12884-022-04945-z
pubmed: 35953773
pmcid: 9368700
Juncker, H. G. et al. Comparing the human milk antibody response after vaccination with four COVID-19 vaccines: a prospective, longitudinal cohort study in the Netherlands. EClinicalMedicine 47, 101393 (2022).
doi: 10.1016/j.eclinm.2022.101393
pubmed: 35465077
pmcid: 9013951
Carlsen, E. O. et al. Association of COVID-19 vaccination during pregnancy with incidence of SARS-CoV-2 infection in infants. JAMA Intern. Med. 226, 177–186 (2022).
Kugelman, N. et al. Third trimester messenger RNA COVID-19 booster vaccination upsurge maternal and neonatal SARS-CoV-2 immunoglobulin G antibody levels at birth. Eur. J. Obstet. Gynecol. Reprod. Biol. 274, 148–154 (2022).
doi: 10.1016/j.ejogrb.2022.05.029
pubmed: 35653903
pmcid: 9148860
Longueira, Y. et al. SARS-CoV-2-Specific IgG and IgA response in maternal blood and breastmilk of vaccinated naive and convalescent lactating participants. Front. Immunol. 13, 909995 (2022).
doi: 10.3389/fimmu.2022.909995
pubmed: 36263055
pmcid: 9574440
Mithal, L. B., Otero, S., Shanes, E. D., Goldstein, J. A. & Miller, E. S. Cord blood antibodies following maternal coronavirus disease 2019 vaccination during pregnancy. Am. J. Obstet. Gynecol. 225, 192–194 (2021).
doi: 10.1016/j.ajog.2021.03.035
pubmed: 33812808
pmcid: 8012273
Beharier, O. et al. Efficient maternal to neonatal transfer of antibodies against SARS-CoV-2 and BNT162b2 mRNA COVID-19 vaccine. J. Clin. Invest. 131, e150319 (2021).
doi: 10.1172/JCI150319
pubmed: 34014840
pmcid: 8245182
Rottenstreich, A. et al. Kinetics of maternally derived anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in infants in relation to the timing of antenatal vaccination. Clin. Infect. Dis. 76, e274–e279 (2022).
Cuningham, W. et al. Optimal timing of influenza vaccine during pregnancy: a systematic review and meta-analysis. Influenza Other Respir. Viruses 13, 438–452 (2019).
doi: 10.1111/irv.12649
pubmed: 31165580
pmcid: 6692549
Skoff, T. H. et al. Impact of the US maternal tetanus, diphtheria, and acellular pertussis vaccination program on preventing pertussis in infants <2 months of age: a case-control evaluation. Clin. Infect. Dis. 65, 1977–1983 (2017).
doi: 10.1093/cid/cix724
pubmed: 29028938
Nunes, M. C. & Madhi, S. A. Influenza vaccination during pregnancy for prevention of influenza confirmed illness in the infants: a systematic review and meta-analysis. Hum. Vaccin. Immunother. 14, 758–766 (2018).
doi: 10.1080/21645515.2017.1345385
pubmed: 28708952
Prunas, O. et al. Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel. Science 375, 1151–1154 (2022).
doi: 10.1126/science.abl4292
pubmed: 35084937
VanderWeele, T. J. & Tchetgen Tchetgen, E. J. Bounding the infectiousness effect in vaccine trials. Epidemiology 22, 686–693 (2011).
doi: 10.1097/EDE.0b013e31822708d5
pubmed: 21753730
pmcid: 3792580
Richterman A., Meyerowitz E. A., Cevik M. Indirect protection by reducing transmission: ending the pandemic with severe acute respiratory syndrome coronavirus 2 vaccination. Open Forum Infect. Dis. 9, ofab259 (2022).